← Back to all trials
Completed
NCT03138733
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
Conditions: Staphylococcus Aureus Bacteremia
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 390
Sponsor: Basilea Pharmaceutica
Location: eStudy Site - Chula Vista - PPDS Chula Vista California
Summary
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
Eligibility Criteria
Inclusion Criteria:
* Male or female ≥ 18 years of age
* Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization
* At least one of the following signs or symptoms of bacteremia:
1. fever (e.g.≥ 38 °C/100.4 °F measured orally)
2. white blood cell count \> 10,000 or \< 4,000 cells/µL, or \> 10% immature neutrophils (bands)
3. tachycardia (heart rate \> 90 bpm)
4. hypotension (systolic blood pressure \< 90 mmHg)
* At least one of the following:
1. SAB in patients undergoing chronic intermittent hemodialysis or peritoneal dialysis
2. Persistent SAB
3. Definite native-valve right-sided infective endocarditis by Modified Duke's Criteria
4. Other forms of complicated SAB
5. Osteomyelitis (including vertebral, sternal, or long-bone osteomyelitis)
6. Epidural or cerebral abscess
* Other inclusion criteria have been applied
Exclusion Criteria:
* Treatment with potentially effective (anti-staphylococcal) systemic antibacterial treatment for more than 48 h within the 7 days prior to randomization; Exception: Documented failure of bloodstream clearance
* Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that are known to be non-susceptible to either ceftobiprole or aztreonam
* Left-sided infective endocarditis
* Prosthetic cardiac valves or valve support rings, cardiac pacemakers, automatic implantable cardioverter-defibrillator, or left-ventricular assist devices
* Community- or hospital-acquired pneumonia
* Opportunistic infections within 30 days prior to randomization, where the underlying cause of these infections is still active
* Requirement for continuous renal-replacement therapy
* Women who are pregnant or nursing
* Other exclusion criteria have been applied
Source: ClinicalTrials.gov (NCT03138733). StuddyBuddy aggregates publicly available trial information.